Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2009. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in beneficial interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The only material change disclosed is the acquisition of a beneficial interest by Mr. S M Bicknell. On January 5, 2009, he acquired 7 ordinary shares through the re-investment of dividends under a Personal Equity Plan at a price of £12.57 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It strictly details a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the identity of Mr. S M Bicknell and his role within the company.
- Confirm the share price of £12.57 per share on January 5, 2009.
- Note that the transaction involved only 7 shares, indicating a minimal impact on overall ownership structure.